Puma Biotechnology Inc (PBYI)

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on June 1, 2026, the Compensation Committee of Puma’s Board...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Puma Biotechnology Reports First Quarter 2026 Financial Results

Raising 2026 Revenue and Net Income Guidance Based on Increased Demand for NERLYNX Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical...

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on May 5, 2026, the Compensation Committee of Puma’s Board...